Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19

ACTIV-3/TICO Bamlanivimab Study Group, Jens D. Lundgren, Birgit Grund, Christina E. Barkauskas, Thomas L. Holland, Robert L. Gottlieb, Uriel Sandkovsky, Samuel M. Brown, Kirk U. Knowlton, Wesley H. Self, D. Clark Files, Mamta K. Jain, Thomas Benfield, Michael E. Bowdish, Bradley G. Leshnower, Jason V. Baker, Jens-Ulrik Jensen, Edward M. Gardner, Adit A. Ginde, Estelle S. Harris, Isik S. Johansen, Norman Markowitz, Michael A. Matthay, Lars Østergaard, Christina C. Chang, Anna Goodman, Weizhong Chang, Robin L. Dewar, Norman P. Gerry, Elizabeth S. Higgs, Helene Highbarger, Daniel D. Murray, Thomas A. Murray, Ven Natarajan, Roger Paredes, Mahesh K.B. Parmar, Andrew N. Phillips, Cavan Reilly, Adam W. Rupert, Shweta Sharma, Kathryn Shaw-Saliba, Brad T. Sherman, Marc Teitelbaum, Deborah Wentworth, Huyen Cao, Paul Klekotka, Abdel G. Babiker, Victoria J. Davey, Annetine C. Gelijns, Virginia L. Kan, Mark N. Polizzotto, B. Taylor Thompson, H. Clifford Lane, James D. Neaton
doi: https://doi.org/10.1101/2021.07.19.21260559
1CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
Jens D. Lundgren
1CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
Roles: protocol chair, Copenhagen INSIGHT ICC lead
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jens.lundgren@regionh.dk
Birgit Grund
2Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis
Roles: lead unblinded statistician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina E. Barkauskas
3Division of Pulmonary, Allergy, and Critical Care Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas L. Holland
4Division of Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert L. Gottlieb
5Department of Medicine, Duke University, Durham, Baylor University Medical Center, Dallas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uriel Sandkovsky
5Department of Medicine, Duke University, Durham, Baylor University Medical Center, Dallas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel M. Brown
6Intermountain Medical Center, Murray
7University of Utah, Salt Lake City
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirk U. Knowlton
7University of Utah, Salt Lake City
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wesley H. Self
8Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Clark Files
9Department of Internal Medicine, Section on Pulmonary, Critical Care, Allergy
10Immunology, Wake Forest School of Medicine, Winston-Salem
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mamta K. Jain
11UT Southwestern Medical Center, Dallas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Benfield
12Department of Infectious Diseases, Copenhagen University Hospital, Amager and Hvidovre, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael E. Bowdish
13Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradley G. Leshnower
14Division of Cardiothoracic Surgery Emory University School of Medicine, Atlanta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason V. Baker
15Hennepin Healthcare Research Institute, Minneapolis and University of Minnesota
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jens-Ulrik Jensen
16Department of Internal Medicine, Respiratory Medicine Section, Herlev
17Gentofte Hospital, University of Copenhagen, Hellerup
18Denmark and Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward M. Gardner
19Denver Public Health, Denver Health and Hospital Authority, Denver
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adit A. Ginde
20Department of Emergency Medicine, University of Colorado School of Medicine, Aurora
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Estelle S. Harris
7University of Utah, Salt Lake City
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isik S. Johansen
21Department of Infectious Diseases, Odense University Hospital, Odense
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norman Markowitz
22Department of Infectious Diseases, Henry Ford Hospital, Detroit
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Matthay
23Department of Medicine, Department of Anesthesia, The University of California, San Francisco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Østergaard
24Aarhus University Hospital, Skejby
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina C. Chang
25The Kirby Institute, University of New South Wales, Sydney
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Goodman
28Guy’s & St. Thomas’ NHS Foundation Trust, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weizhong Chang
35Laboratory of Molecular Cell Biology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin L. Dewar
32Leidos Biomedical Research, Inc., Frederick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norman P. Gerry
33Advanced Biomedical Laboratories, LLC., Cinnaminson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth S. Higgs
29National Institute of Allergy and Infectious Diseases, Bethesda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helene Highbarger
32Leidos Biomedical Research, Inc., Frederick
36AIDS Monitoring Laboratory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel D. Murray
1CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas A. Murray
2Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ven Natarajan
36AIDS Monitoring Laboratory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Paredes
30Infectious Diseases Department & irsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Catalonia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahesh K.B. Parmar
27Medical Research Council Clinical Trials Unit at UCL, University College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew N. Phillips
31Institute for Global Health, University College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cavan Reilly
2Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam W. Rupert
37Frederick National Laboratory for Cancer Research, Frederick, Gilead Sciences, Foster City
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shweta Sharma
2Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn Shaw-Saliba
29National Institute of Allergy and Infectious Diseases, Bethesda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brad T. Sherman
35Laboratory of Molecular Cell Biology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Teitelbaum
32Leidos Biomedical Research, Inc., Frederick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah Wentworth
2Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huyen Cao
37Frederick National Laboratory for Cancer Research, Frederick, Gilead Sciences, Foster City
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Klekotka
38Eli Lilly and Company, Indianapolis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abdel G. Babiker
27Medical Research Council Clinical Trials Unit at UCL, University College London
Roles: London INSIGHT ICC lead
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria J. Davey
26Department of Veterans Affairs, Washington, D.C
Roles: VA ICC lead
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annetine C. Gelijns
27Medical Research Council Clinical Trials Unit at UCL, University College London
40Veteran Affairs Medical Center, Washington, D.C
Roles: CTSN ICC lead
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginia L. Kan
41George Washington University School of Medicine and Health Sciences, Washington
Roles: Washington INSIGHT ICC lead
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark N. Polizzotto
25The Kirby Institute, University of New South Wales, Sydney
42St Vincent’s Hospital, Sydney
Roles: Sydney INSIGHT ICC lead
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Taylor Thompson
3Division of Pulmonary, Allergy, and Critical Care Medicine
44Harvard Medical School Boston
Roles: PETAL ICC lead
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Clifford Lane
29National Institute of Allergy and Infectious Diseases, Bethesda
Roles: DCR NIAID lead
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James D. Neaton
2Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis
Roles: INSIGHT PI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

BACKGROUND Bamlanivimab, a neutralizing monoclonal antibody given in combination with remdesivir, did not improve outcomes among hospitalized COVID-19 patients based on an early futility assessment. In this final study report, we evaluate an a priori hypothesis that greater benefit of bamlanivimab would be identified in those without detectable endogenous neutralizing antibody levels at study entry, especially if viral levels were high.

METHODS Hospitalized COVID-19 patients were randomized to receive bamlanivimab (7000mg) or placebo and followed for 90 days for sustained recovery (home for 14 consecutive days); recovery rate ratios (RRRs) are cited.

RESULTS Among 314 participants (163 on bamlanivimab and 151 on placebo), the median time to sustained recovery was 19 days and RRR=0.99 (95% CI: 0.79-1.22; p=0.89). At entry, 50% evidenced production of anti-spike neutralizing antibodies; 50% had SARS-CoV-2 nucleocapsid plasma antigen levels ≥ 1,000 ng/L. Among those without and with antibodies at study entry, the RRRs were 1.24 (95% CI: 0.90-1.70) and 0.74 (95% CI: 0.54-1.00) (p=0.02 for interaction). The RRRs were elevated for those with plasma antigen or nasal viral RNA levels above versus below median at entry, and was greatest for those without antibodies and with elevated antigen or viral RNA levels: 1.48 (95% CI: 0.99-2.23), 1.94 (1.25-3.00), respectively (p<0.05 for all interactions). Hazard ratios for safety outcomes also differed by serostatus at entry.

CONCLUSIONS Sustained recovery after administration of bamlanivimab versus placebo differed by presence of neutralizing antibodies at study entry, especially if participants had markers of elevated viral replication.

ClinicalTrials.gov number, NCT04501978.

Competing Interest Statement

Mixed competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; AGB has received research grants from the University of Minnesota, USA and the Medical Research Council, UK, AAG has received a research grant from NHLBI, ACG has received research grants from the NIH, BTT has received research grants from NHLBI, Birgit Grund has received research grants from the NIH, DCF has received research grants from the NIH and reports personal fees from Cytovale outside the submitted work, EMG has received research grants from NIAID, HC reports other from Gilead Sciences, outside the submitted work, JDN has received research grants from NIH and NIAID, LO reports personal fees from a lecture given at Gilead Sciences in 2008 outside the submitted work, MKJ reports grants and personal fees from Gilead Sciences and grants from Regeneron outside the submitted work, MAM reports grants from Roche-Genentech, personal fees from Novartis Pharmaceuticals, personal fees from Citius Pharmaceuticals, grants from Department of Defense, grants from NIH/NHLBI, grants from California Institute of Regenerative Medicine, outside the submitted work, PK reports personal fees from Eli Lilly, during the conduct of the study; personal fees from Eli Lilly, outside the submitted work, RLG reports personal fees and non-financial support from Gilead Sciences, Inc., outside the submitted work, RP reports grants and personal fees from Gilead, grants and personal fees from MSD, grants and personal fees from ViiV Healthcare, outside the submitted work, SMB reports grants from NIH, during the conduct of the study; personal fees from Hamilton, other from Faron, other from Sedana, grants from Janssen, grants from NIH, grants from DoD, other from Oxford University, other from Brigham Young University, personal fees from NYU, outside the submitted work, SS reports grants from NIH, during the conduct of the study, TLH reports personal fees from Basilea Pharmaceutica (ceftobiprole), personal fees from Motif Bio (iclaprim), personal fees from Genentech (immunotherapeutic), outside the submitted work, TB reports grants from Novo Nordisk Foundation, grants from Simonsen Foundation, grants and personal fees from GSK, grants and personal fees from Pfizer, personal fees from Boehringer Ingelheim, grants and personal fees from Gilead, personal fees from MSD, grants from Lundbeck Foundation, grants from Kai Hansen Foundation, outside the submitted work, US reports grants from National Institutes of Health, during the conduct of the study; grants from Regeneron, grants from National Institues of Health, grants from Cytodyn, outside the submitted work, WHS reports grants from National Heart, Lung, and Blood Institute, during the conduct of the study; personal fees from Aerpio Pharmaceuticals, outside the submitted work.

Clinical Trial

NCT04501978

Funding Statement

The trial was primarily funded by Operation Warp Speed, with the support of NIAID, NIH Grant U01-AI136780, and the Division of Clinical Research and Leidos Biomedical Research, Inc., Contract HHSN261200800001E, for the INSIGHT Network, and NHLBI and the Research Triangle Institute for the PETAL and CTSN Networks. Other funding and support was provided by the U.S. Departments of Veterans Affairs, and the governments of Denmark (National Research Foundation; grant no 126), Australia (National Health and Medical Research Council), and U.K. (Medical Research Council, MRC_UU_12023/23). Study medications were donated by Gilead Sciences, and Eli Lilly.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The following ethics committees approved the TICO protocol for the Bamlanivimab part of the study (protocol v1.0): US: central IRB- Advarra UK: South Central - Berkshire Research Ethics Committee Greece: Hellenic Republic, Minister of Health and Welfare, National Ethic Committee Uganda: The Uganda Virus Research Institute Research and Ethics Committee Singapore: National Healthcare Group Domain-Specific Review Board Denmark: De Videnskabsetiske Komiteer for Region Hovedstaden Spain: Comite d Etica de la Investigacio amb medicaments, Hospital Universitari Germans Trias i Pujol Poland: Komisja Bioetyczna przy Uniwersytecie Warszawskim At the time of discontinuation of the Bamlanivimab part of the TICO study, no other IRB disapproved of the study or waived approval.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* A complete list of members in the ACTIV-3/TICO Bamlanivimab Study Group is provided in the Supplementary Appendix.

Data Availability

The data set used for this manuscript is available upon request to the INSIGHT scientific steering committee at insightsscsec.rigshospitalet{at}regionh.dk

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 22, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19
ACTIV-3/TICO Bamlanivimab Study Group, Jens D. Lundgren, Birgit Grund, Christina E. Barkauskas, Thomas L. Holland, Robert L. Gottlieb, Uriel Sandkovsky, Samuel M. Brown, Kirk U. Knowlton, Wesley H. Self, D. Clark Files, Mamta K. Jain, Thomas Benfield, Michael E. Bowdish, Bradley G. Leshnower, Jason V. Baker, Jens-Ulrik Jensen, Edward M. Gardner, Adit A. Ginde, Estelle S. Harris, Isik S. Johansen, Norman Markowitz, Michael A. Matthay, Lars Østergaard, Christina C. Chang, Anna Goodman, Weizhong Chang, Robin L. Dewar, Norman P. Gerry, Elizabeth S. Higgs, Helene Highbarger, Daniel D. Murray, Thomas A. Murray, Ven Natarajan, Roger Paredes, Mahesh K.B. Parmar, Andrew N. Phillips, Cavan Reilly, Adam W. Rupert, Shweta Sharma, Kathryn Shaw-Saliba, Brad T. Sherman, Marc Teitelbaum, Deborah Wentworth, Huyen Cao, Paul Klekotka, Abdel G. Babiker, Victoria J. Davey, Annetine C. Gelijns, Virginia L. Kan, Mark N. Polizzotto, B. Taylor Thompson, H. Clifford Lane, James D. Neaton
medRxiv 2021.07.19.21260559; doi: https://doi.org/10.1101/2021.07.19.21260559
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19
ACTIV-3/TICO Bamlanivimab Study Group, Jens D. Lundgren, Birgit Grund, Christina E. Barkauskas, Thomas L. Holland, Robert L. Gottlieb, Uriel Sandkovsky, Samuel M. Brown, Kirk U. Knowlton, Wesley H. Self, D. Clark Files, Mamta K. Jain, Thomas Benfield, Michael E. Bowdish, Bradley G. Leshnower, Jason V. Baker, Jens-Ulrik Jensen, Edward M. Gardner, Adit A. Ginde, Estelle S. Harris, Isik S. Johansen, Norman Markowitz, Michael A. Matthay, Lars Østergaard, Christina C. Chang, Anna Goodman, Weizhong Chang, Robin L. Dewar, Norman P. Gerry, Elizabeth S. Higgs, Helene Highbarger, Daniel D. Murray, Thomas A. Murray, Ven Natarajan, Roger Paredes, Mahesh K.B. Parmar, Andrew N. Phillips, Cavan Reilly, Adam W. Rupert, Shweta Sharma, Kathryn Shaw-Saliba, Brad T. Sherman, Marc Teitelbaum, Deborah Wentworth, Huyen Cao, Paul Klekotka, Abdel G. Babiker, Victoria J. Davey, Annetine C. Gelijns, Virginia L. Kan, Mark N. Polizzotto, B. Taylor Thompson, H. Clifford Lane, James D. Neaton
medRxiv 2021.07.19.21260559; doi: https://doi.org/10.1101/2021.07.19.21260559

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9767)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1559)
  • Health Policy (735)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11641)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (517)
  • Oncology (1176)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4657)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)